Centessa Pharmaceuticals (CNTA) Accumulated Depreciation & Amortization (2021 - 2026)
Centessa Pharmaceuticals (CNTA) reported Accumulated Depreciation & Amortization of $239000.0 for Q1 2026, up 10.14% year-over-year from $217000.0 in Q1 2025, and down 74.05% on a QoQ basis from $921000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 6 years of Accumulated Depreciation & Amortization data on file, last reported at $239000.0 in Q1 2026.
- Quarterly Accumulated Depreciation & Amortization rose 10.14% year-over-year to $239000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $239000.0 (up 10.14% YoY) and the FY2025 annual result came in at $921000.0, down 2.23% from the prior year.
- Accumulated Depreciation & Amortization fell to $239000.0 in Q1 2026 per CNTA's latest filing, from $921000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $942000.0 in Q4 2024 and bottomed at $28000.0 in Q1 2022.
- The 5-year median for Accumulated Depreciation & Amortization is $326000.0 (2023), against an average of $410176.5.
- The widest annual swing landed in 2022, when Accumulated Depreciation & Amortization surged 1300.0%; it then retreated 9.58% in 2025.
- Tracing CNTA's Accumulated Depreciation & Amortization over 5 years: stood at $131000.0 in 2022, then surged by 518.32% to $810000.0 in 2023, then advanced by 16.3% to $942000.0 in 2024, then decreased by 2.23% to $921000.0 in 2025, then plunged by 74.05% to $239000.0 in 2026.
- Per Business Quant, the three latest CNTA Accumulated Depreciation & Amortization figures stand at $239000.0 (Q1 2026), $921000.0 (Q4 2025), and $680000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 239,000.00 |
| Mar 31, 2026 | 239,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Sep 30, 2025 | 680,000.00 |
| Sep 30, 2025 | 680,000.00 |
| Jun 30, 2025 | 443,000.00 |
| Jun 30, 2025 | 443,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Mar 31, 2025 | 217,000.00 |
| Dec 31, 2024 | 942,000.00 |
| Dec 31, 2024 | 942,000.00 |
| Sep 30, 2024 | 712,000.00 |
| Sep 30, 2024 | 712,000.00 |
| Jun 30, 2024 | 476,000.00 |
| Jun 30, 2024 | 476,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | 810,000.00 |
| Dec 31, 2023 | 810,000.00 |
| Sep 30, 2023 | 564,000.00 |
| Sep 30, 2023 | 564,000.00 |
| Jun 30, 2023 | 326,000.00 |
| Jun 30, 2023 | 326,000.00 |
| Mar 31, 2023 | 89,000.00 |
| Mar 31, 2023 | 89,000.00 |
| Dec 31, 2022 | 131,000.00 |
| Dec 31, 2022 | 131,000.00 |
| Sep 30, 2022 | 95,000.00 |
| Sep 30, 2022 | 95,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 28,000.00 |
| Mar 31, 2022 | 28,000.00 |
| Dec 31, 2021 | 34,000.00 |
| Dec 31, 2021 | 34,000.00 |
| Sep 30, 2021 | 22,000.00 |
| Sep 30, 2021 | 22,000.00 |
| Jun 30, 2021 | 9,000.00 |
| Jun 30, 2021 | 9,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Mar 31, 2021 | 2,000.00 |